Literature DB >> 32968828

Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.

Matthew Schwede1, Irena T Tan2, Danielle F Atibalentja2, Meghan M Dickman3, Kerri E Rieger3,4, Gabriel N Mannis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32968828     DOI： 10.1007/s00277-020-04276-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

1.  Identification of a leukemic counterpart of the plasmacytoid dendritic cells.

Authors:  L Chaperot; N Bendriss; O Manches; R Gressin; M Maynadie; F Trimoreau; H Orfeuvre; B Corront; J Feuillard; J J Sotto; J C Bensa; F Brière; J Plumas; M C Jacob
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

2.  Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

Authors:  Joan Montero; Jason Stephansky; Tianyu Cai; Gabriel K Griffin; Lucia Cabal-Hierro; Katsuhiro Togami; Leah J Hogdal; Ilene Galinsky; Elizabeth A Morgan; Jon C Aster; Matthew S Davids; Nicole R LeBoeuf; Richard M Stone; Marina Konopleva; Naveen Pemmaraju; Anthony Letai; Andrew A Lane
Journal:  Cancer Discov       Date:  2016-12-16       Impact factor: 39.397

3.  Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients.

Authors:  F Julia; T Petrella; M Beylot-Barry; M Bagot; D Lipsker; L Machet; P Joly; O Dereure; M Wetterwald; M d'Incan; F Grange; J Cornillon; G Tertian; E Maubec; P Saiag; S Barete; I Templier; F Aubin; S Dalle
Journal:  Br J Dermatol       Date:  2013-09       Impact factor: 9.302

4.  Clinical and biologic features of CD4(+)CD56(+) malignancies.

Authors:  Jean Feuillard; Marie-Christine Jacob; Françoise Valensi; Marc Maynadié; Rémy Gressin; Laurence Chaperot; Christine Arnoulet; Françoise Brignole-Baudouin; Bernard Drénou; Eliane Duchayne; Annie Falkenrodt; Richard Garand; Emanuelle Homolle; Bernard Husson; Emilienne Kuhlein; Geneviève Le Calvez; Danielle Sainty; Marie-France Sotto; Franck Trimoreau; Marie-Christine Béné
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

5.  Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Authors:  Naveen Pemmaraju; Andrew A Lane; Kendra L Sweet; Anthony S Stein; Sumithira Vasu; William Blum; David A Rizzieri; Eunice S Wang; Madeleine Duvic; J Mark Sloan; Sharon Spence; Shay Shemesh; Christopher L Brooks; John Balser; Ivan Bergstein; Jeffrey E Lancet; Hagop M Kantarjian; Marina Konopleva
Journal:  N Engl J Med       Date:  2019-04-25       Impact factor: 91.245

6.  TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin.

Authors:  Marco Herling; Michael A Teitell; Rhine R Shen; L Jeffrey Medeiros; Dan Jones
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

Authors:  Livio Pagano; Caterina Giovanna Valentini; Alessandro Pulsoni; Simona Fisogni; Paola Carluccio; Francesco Mannelli; Monia Lunghi; Gianmatteo Pica; Francesco Onida; Chiara Cattaneo; Pier Paolo Piccaluga; Eros Di Bona; Elisabetta Todisco; Pellegrino Musto; Antonio Spadea; Alfonso D'Arco; Stefano Pileri; Giuseppe Leone; Sergio Amadori; Fabio Facchetti
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

Authors:  Courtney D DiNardo; Caitlin R Rausch; Christopher Benton; Tapan Kadia; Nitin Jain; Naveen Pemmaraju; Naval Daver; Wendy Covert; Kayleigh R Marx; Morgan Mace; Elias Jabbour; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Kapil N Bhalla; Hagop Kantarjian; Marina Konopleva
Journal:  Am J Hematol       Date:  2017-12-23       Impact factor: 13.265
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.